Pomerantz LLP is investigating Sellas Life Sciences Group and some of its executives for potential securities fraud related to the delayed release of phase 3 clinical trial results for their drug Galinpepimut-S. The trial reached a key milestone of 80 patient deaths on August 28, 2026, which should have triggered the release of results, but Sellas did not disclose them promptly. Following the news report about the delay, Sellas's stock price fell 13.15% in one day. The investigation aims to determine if the company engaged in unlawful business practices, and investors affected are encouraged to contact Pomerantz LLP for possible class action participation.
Sellas Life Sciences Group's stock fell 13.15% in one day following news of delayed clinical trial results. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced US health stocks, 59 rose and 31 fell. Notable movers include Illumina, Inc. (ILMN) at USD 241.64 with a 5.55% gain but 97% sell order activity, Ginkgo Bioworks Holdings Inc (DNA) at USD 7.44 up 5.38%, and Citius Pharmaceuticals Inc (CTXR) at USD 0.58 up 4.20% with 100% buy order activity and a typical hold time of 15 days on Pluang.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
